Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BX Other drugs affecting bone structure and mineralization
M05BX04 Denosumab
D03684 Denosumab (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastic Adjuncts/Mitigators
Denosumab
D03684 Denosumab (USAN)
Metabolic Bone Disease Agents
RANK Ligand Inhibitors
Denosumab
D03684 Denosumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03684 Denosumab (USAN); Denosumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D03684 Denosumab
Musculo-skeletal system agent
DG03232 Osteoporosis agent
D03684 Denosumab
Drug classes [BR:br08332]
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D03684 Denosumab
Musculo-skeletal system agent
DG03232 Osteoporosis agent
D03684 Denosumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNFSF11 (RANKL, CD254)
D03684 Denosumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03684
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03684
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03684
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03684